This award recognises a European Pharma or large-cap Biotech company that has demonstrated superior excellence in strategy, process, focus and execution and contributed to the broader life science industry.
- Open to all pharma companies and large cap large cap biotech companies with a market capitalisation that is $10bn or above.
- Open to all pharma / large cap companies with European Headquarters
- Criteria relates to the period between 1 September 2019 and 1 September 2020
Judges will be paying particular attention to:- Targeting of unmet medical need / use of innovative approaches to product development- Pipeline progress through in-development / clinical stages / market approval- Closure of fundraises and strategic financing rounds- Key stages of strategic development / partnerships- Implementation of new technologies, processes for strategic advantage
- Wider industry contribution and advocacy